Dr. Lal PathLabs Limited
LALPATHLAB
Kedudukan dalam Saham
#4527
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health... Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Harga Saham
$20.35
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.40B
Perubahan (1 hari)
-0.86%
Perubahan (1 tahun)
14.21%
Negara
IN
Perdagangan Dr. Lal PathLabs Limited (LALPATHLAB)
Kategori
Healthcare
Hasil untuk Dr. Lal PathLabs Limited (LALPATHLAB)
Hasil pada Jun 2026 TTM: $319.03M
Menurut laporan kewangan terkini daripada Dr. Lal PathLabs Limited, hasil semasa syarikat (TTM) ialah $319.03M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $267.04M peningkatan berbanding hasil pada tahun 2023 iaitu $245.42M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Dr. Lal PathLabs Limited dari 2011 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $319.03M | 10.85% |
| 2025 | $287.79M | 7.77% |
| 2024 | $267.04M | 8.81% |
| 2023 | $245.42M | -10.75% |
| 2022 | $274.99M | 27.30% |
| 2021 | $216.01M | 22.32% |
| 2020 | $176.59M | 1.90% |
| 2019 | $173.30M | 6.76% |
| 2018 | $162.33M | 15.38% |
| 2017 | $140.69M | 17.79% |
| 2016 | $119.44M | 13.00% |
| 2015 | $105.71M | -3.94% |
| 2014 | $110.04M | 32.38% |
| 2013 | $83.13M | 23.17% |
| 2012 | $67.49M | 26.76% |
| 2011 | $53.24M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $46.34B | 14,424.25% |
US
|
|
| $25.11B | 7,769.91% |
US
|
|
| $2.71B | 748.55% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 2,210.79% |
US
|
